Srpski arhiv za celokupno lekarstvo 2012 Volume 140, Issue 7-8, Pages: 425-430
https://doi.org/10.2298/SARH1208425D
Full text ( 401 KB)
Prospective follow-up of nebivolol in the treatment of arterial hypertension
Despotović Nebojša (Medicinski fakultet, Beograd + Kliničko-bolnički centar „Zvezdara”, Beograd)
Matić-Cvetković Danica (Medicinski fakultet, Beograd + Klinički centar Srbije, Beograd)
Ivanović Branislava (Medicinski fakultet, Beograd + Klinički centar Srbije, Beograd)
Introduction. Nebivolol, a third-generation beta-blocker (BB) shows a highly
selective beta-blockade and specific vasodilating effects due to getting free
nitro-oxide from the dysfunctional endothelium. Objective. The aim of the
study was to investigate the antihypertensive effect of nebivolol in patients
with arterial hypertension (AH) of both sexes. Methods. Systolic and
diastolic blood pressure (BP), heart rate and serum glycemia, creatinin,
cholesterol and trygliceride were measured after a 6-week treatment with a
single 5 mg dose of nebivolol once daily so as to assess its efficacy and
metabolic effects, as well as its tolerance by using a questionnaire answered
by physicians and patients. Results. Out of 520 patients with mild or
moderate AH, 430 (82.7%) were treated with nebivolol as monotherapy. After a
6-week treatment with nebivolol, with very good tolerability and neutral
metabolic effects, systolic BP was significantly decreased (in male from
initial 165±19 to 129±12 mm Hg, and female from initial 169±22 to 132±15 mm
Hg at the end of the study; average decrease 22.3%, p<0.001) and as well as
diastolic BP (male from initial 103±12 to 79±6 mm Hg and female from initial
100±9 to 82±7 mm Hg, average decrease 22.6%; p<0.001). Conclusion. After a
6-week treatment nebivolol significantly decreased systolic and diastolic BP
in patients with mild and moderate AH, independently of the sex.
Keywords: arterial hypertension, beta-blocker, nitro-oxide